LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 12

Search options

  1. Article ; Online: An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.

    Ni, Yawei / Guo, Jianhua / Turner, Debra / Tizard, Ian

    Frontiers in immunology

    2018  Volume 9, Page(s) 1815

    Abstract: Current inactivated influenza vaccines are strain-specific and poorly effective against variant or mismatched viruses. They are standardized based on their hemagglutinin (HA) or ability to induce strain-specific hemagglutination inhibition (HAI) ... ...

    Abstract Current inactivated influenza vaccines are strain-specific and poorly effective against variant or mismatched viruses. They are standardized based on their hemagglutinin (HA) or ability to induce strain-specific hemagglutination inhibition (HAI) antibodies. The HA is known to undergo major conformational changes when exposed to the low pH environment of endosomes (pH 5.0 and 37°C), which are required for membrane fusion during virus cell entry. In an effort to improve these vaccines, influenza antigens treated under various low pH conditions were evaluated for increased cross-reactive antibody response and cross protection. It was found that a full range of structural and antigenic changes in HA could be induced by varying low pH treatment conditions from the mild (low pH at ≤25°C) to the strong (low pH at ≥37°C) as determined by analysis of potency, HA morphology, protease sensitivity, and reactivity with an anti-HA2 domain (CD) antibody. Inactivated antigens of both H1N1 and H3N2 strains treated at mild low pH conditions (0-25°C) exhibited only moderate HA structural and antigenic changes and markedly increased antibody response against HA2, the highly conserved part of HA, and cross protection against heterologous challenge in mice by up to 30% in survival. By contrast, antigen treated with low pH at 37°C showed more extensive structural and antigenic changes, and induced much less of an increase in antibody response against HA2, but a greater increase with response against HA1, and did not provide any increased cross protection. These results suggest that the increased response against HA2 obtained with the mild low pH treatment is associated with the increased cross protection. These antigens treated at the mild low pH conditions remained capable of inducing a high level of strain-specific HAI antibodies. Thus, they could readily be formulated as an inactivated influenza vaccine which not only provides the same strain-specific protection but also an increased cross protection against heterologous viruses. Such a vaccine could be particularly beneficial in cases of vaccine mismatch.
    MeSH term(s) Animals ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Cross Protection/immunology ; Cross Reactions ; Enzyme-Linked Immunosorbent Assay ; Hemagglutination Inhibition Tests ; Hemagglutinin Glycoproteins, Influenza Virus/immunology ; Humans ; Hydrogen-Ion Concentration ; Immunization ; Immunogenicity, Vaccine ; Influenza A virus/classification ; Influenza A virus/immunology ; Influenza A virus/ultrastructure ; Influenza Vaccines/administration & dosage ; Influenza Vaccines/immunology ; Influenza, Human/immunology ; Influenza, Human/prevention & control ; Mice ; Neutralization Tests ; Orthomyxoviridae Infections/immunology ; Orthomyxoviridae Infections/prevention & control ; Vaccines, Inactivated/administration & dosage ; Vaccines, Inactivated/immunology
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Hemagglutinin Glycoproteins, Influenza Virus ; Influenza Vaccines ; Vaccines, Inactivated
    Language English
    Publishing date 2018-08-09
    Publishing country Switzerland
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2018.01815
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Development of a novel dual-domain nanoparticle antigen construct for universal influenza vaccine

    Ni, Yawei / Guo, Jianhua / Turner, Debra / Tizard, Ian

    Vaccine. 2017 Dec. 15, v. 35, no. 50

    2017  

    Abstract: A highly effective antigen construct for presenting conserved antigen domains is essential to the development of a universal influenza vaccine. We have developed a novel dual-domain nanoparticle fusion protein (DDNFP) which allows independent ... ...

    Abstract A highly effective antigen construct for presenting conserved antigen domains is essential to the development of a universal influenza vaccine. We have developed a novel dual-domain nanoparticle fusion protein (DDNFP) which allows independent presentation of two conserved domains. The conserved domains used were from two separate viral surface proteins, M2e of M2 and fusion peptide (FP) or long alpha helix (CD) of HA2. The carrier is a novel nanoparticle protein – the dodecameric DNA binding protein from starved cells (Dps) of bacteria or archaea. Dps was found to be uniquely capable of simultaneous fusion and surface presentation at both N- and C-termini while retaining the ability to form nanoparticles. Thus, DDNFPs with M2e and FP or CD fused at N- and C-termini of Dps from E. coli (EcDps) or other bacteria were first constructed based on the H1 subtype sequences along with corresponding single-domain nanoparticle fusion proteins (SDNFPs). They were expressed at high levels in bacteria and found to form nanoparticles of the expected size (∼9 nm). They were stable against treatment at high temperatures. The DDNFPs (M2e-EcDps-FP and M2e-EcDps-CD) induced strong antibody responses against individual antigen domains and provided full protection against lethal challenge with PR8 virus (H1N1). Importantly, the protection by DDNFPs was synergistically enhanced as compared to SDNFPs. The M2e-EcDps-CD provided an even stronger protection than M2e-EcDps-FP and therefore appeared to be the superior construct. Together, with novel domain combination, enhanced protection and ease of production, this M2e/CD DDNFP could potentially be a highly effective antigen construct for the universal influenza vaccine.
    Keywords Archaea ; DNA-binding proteins ; Escherichia coli ; Influenza A virus ; antibodies ; antigens ; bacteria ; influenza vaccines ; nanoparticles ; surface proteins ; temperature ; viruses
    Language English
    Dates of publication 2017-1215
    Size p. 7026-7032.
    Publishing place Elsevier Ltd
    Document type Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2017.10.051
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  3. Article ; Online: Development of a novel dual-domain nanoparticle antigen construct for universal influenza vaccine.

    Ni, Yawei / Guo, Jianhua / Turner, Debra / Tizard, Ian

    Vaccine

    2017  Volume 35, Issue 50, Page(s) 7026–7032

    Abstract: A highly effective antigen construct for presenting conserved antigen domains is essential to the development of a universal influenza vaccine. We have developed a novel dual-domain nanoparticle fusion protein (DDNFP) which allows independent ... ...

    Abstract A highly effective antigen construct for presenting conserved antigen domains is essential to the development of a universal influenza vaccine. We have developed a novel dual-domain nanoparticle fusion protein (DDNFP) which allows independent presentation of two conserved domains. The conserved domains used were from two separate viral surface proteins, M2e of M2 and fusion peptide (FP) or long alpha helix (CD) of HA2. The carrier is a novel nanoparticle protein - the dodecameric DNA binding protein from starved cells (Dps) of bacteria or archaea. Dps was found to be uniquely capable of simultaneous fusion and surface presentation at both N- and C-termini while retaining the ability to form nanoparticles. Thus, DDNFPs with M2e and FP or CD fused at N- and C-termini of Dps from E. coli (EcDps) or other bacteria were first constructed based on the H1 subtype sequences along with corresponding single-domain nanoparticle fusion proteins (SDNFPs). They were expressed at high levels in bacteria and found to form nanoparticles of the expected size (∼9 nm). They were stable against treatment at high temperatures. The DDNFPs (M2e-EcDps-FP and M2e-EcDps-CD) induced strong antibody responses against individual antigen domains and provided full protection against lethal challenge with PR8 virus (H1N1). Importantly, the protection by DDNFPs was synergistically enhanced as compared to SDNFPs. The M2e-EcDps-CD provided an even stronger protection than M2e-EcDps-FP and therefore appeared to be the superior construct. Together, with novel domain combination, enhanced protection and ease of production, this M2e/CD DDNFP could potentially be a highly effective antigen construct for the universal influenza vaccine.
    MeSH term(s) Animals ; Antibodies, Viral/blood ; Antigens, Viral/genetics ; Antigens, Viral/immunology ; Bacterial Proteins/administration & dosage ; Bacterial Proteins/genetics ; DNA-Binding Proteins/administration & dosage ; DNA-Binding Proteins/genetics ; Drug Carriers/administration & dosage ; Hemagglutinin Glycoproteins, Influenza Virus/genetics ; Hemagglutinin Glycoproteins, Influenza Virus/immunology ; Influenza Vaccines/administration & dosage ; Influenza Vaccines/genetics ; Influenza Vaccines/immunology ; Mice, Inbred BALB C ; Nanoparticles/administration & dosage ; Recombinant Fusion Proteins/genetics ; Recombinant Fusion Proteins/immunology ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/genetics ; Vaccines, Synthetic/immunology ; Viral Matrix Proteins/genetics ; Viral Matrix Proteins/immunology
    Chemical Substances Antibodies, Viral ; Antigens, Viral ; Bacterial Proteins ; DNA-Binding Proteins ; DPS protein, Bacteria ; Drug Carriers ; Hemagglutinin Glycoproteins, Influenza Virus ; Influenza Vaccines ; M2 protein, Influenza A virus ; Recombinant Fusion Proteins ; Vaccines, Synthetic ; Viral Matrix Proteins
    Language English
    Publishing date 2017-11-06
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2017.10.051
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Development of a synthetic Vi polysaccharide vaccine for typhoid fever.

    Ni, Yawei / Springer, Michael J / Guo, Jianhua / Finger-Baker, Isaac / Wilson, James P / Cobb, Ronald R / Turner, Debra / Tizard, Ian

    Vaccine

    2017  Volume 35, Issue 51, Page(s) 7121–7126

    Abstract: Typhoid fever remains a serious public health problem with a high impact on toddlers and young children. Vaccines against the Vi capsular polysaccharide are efficacious against typhoid fever demonstrating that antibodies against Vi confer protection. The ...

    Abstract Typhoid fever remains a serious public health problem with a high impact on toddlers and young children. Vaccines against the Vi capsular polysaccharide are efficacious against typhoid fever demonstrating that antibodies against Vi confer protection. The currently licensed Vi typhoid vaccines have however limited efficacy and are manufactured by a complex process from wild-type bacteria. Due to these inherent issues with the current vaccines, an alternative vaccine based on an O-acetylated high molecular weight (HMW) polygalacturonic acid (GelSite-OAc™) was generated. The HMW polygalacturonic acid shares the same backbone as the Vi polysaccharide of Salmonella Typhi. The GelSite-OAc™ has a high molecular weight (>1 × 10
    MeSH term(s) Acetylation ; Animals ; Antibodies, Bacterial/blood ; Antibody Formation/immunology ; Disease Models, Animal ; Immunization, Secondary ; Immunogenicity, Vaccine ; Immunoglobulin G/blood ; Immunologic Memory ; Mice ; Pectins/administration & dosage ; Pectins/chemistry ; Pectins/immunology ; Polysaccharides, Bacterial/administration & dosage ; Polysaccharides, Bacterial/chemistry ; Polysaccharides, Bacterial/immunology ; Salmonella typhi/immunology ; Typhoid Fever/immunology ; Typhoid Fever/microbiology ; Typhoid Fever/prevention & control ; Typhoid-Paratyphoid Vaccines/administration & dosage ; Typhoid-Paratyphoid Vaccines/chemistry ; Typhoid-Paratyphoid Vaccines/immunology ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/chemistry ; Vaccines, Synthetic/immunology
    Chemical Substances Antibodies, Bacterial ; Immunoglobulin G ; Polysaccharides, Bacterial ; Typhoid-Paratyphoid Vaccines ; Vaccines, Synthetic ; Vi polysaccharide vaccine, typhoid ; Pectins (89NA02M4RX) ; polygalacturonic acid (VV3XD4CL04)
    Language English
    Publishing date 2017-11-14
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2017.10.081
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Development of a synthetic Vi polysaccharide vaccine for typhoid fever

    Ni, Yawei / Springer, Michael J / Guo, Jianhua / Finger-Baker, Isaac / Wilson, James P / Cobb, Ronald R / Turner, Debra / Tizard, Ian

    Vaccine. 2017 Dec. 18, v. 35, no. 51

    2017  

    Abstract: Typhoid fever remains a serious public health problem with a high impact on toddlers and young children. Vaccines against the Vi capsular polysaccharide are efficacious against typhoid fever demonstrating that antibodies against Vi confer protection. The ...

    Abstract Typhoid fever remains a serious public health problem with a high impact on toddlers and young children. Vaccines against the Vi capsular polysaccharide are efficacious against typhoid fever demonstrating that antibodies against Vi confer protection. The currently licensed Vi typhoid vaccines have however limited efficacy and are manufactured by a complex process from wild-type bacteria. Due to these inherent issues with the current vaccines, an alternative vaccine based on an O-acetylated high molecular weight (HMW) polygalacturonic acid (GelSite-OAcTM) was generated. The HMW polygalacturonic acid shares the same backbone as the Vi polysaccharide of Salmonella Typhi. The GelSite-OAcTM has a high molecular weight (>1 × 106 Da) and a high degree of O-acetylation (DOAc) (>5 μmole/mg), both exceeding the potency specifications of the current Vi vaccine. Studies in Balb/c mice demonstrated that GelSite-OAcTM was highly immunogenic, inducing a strong antigen-specific antibody response in a DOAc- and dose-dependent manner which was comparable to or higher than those induced by the licensed Vi vaccine. Importantly, the GelSite-OAcTM was shown to be fully protective in mice against lethal challenge with Salmonella Typhi. Furthermore, the GelSite-OAcTM demonstrated a boosting effect or memory response, exhibiting a >2-fold increase in antibody levels upon the second immunization with either GelSite-OAcTM or the Vi vaccine. This novel boosting effect is unique among polysaccharide antigens and potentially makes GelSite-OAcTM effective in people under 2 years old. Together these results suggest that the GelSite-OAcTM could be a highly effective vaccine against Salmonella Typhi.
    Keywords Salmonella Typhi ; antibodies ; antigen-antibody reactions ; antigens ; bacteria ; children ; dose response ; immunization ; mice ; molecular weight ; polysaccharides ; toddlers ; typhoid fever ; vaccine development ; vaccines
    Language English
    Dates of publication 2017-1218
    Size p. 7121-7126.
    Publishing place Elsevier Ltd
    Document type Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2017.10.081
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  6. Article: Stabilization of growth factors relevant to wound healing by a plant cell wall biomaterial.

    Ni, Yawei / Turner, Debra / Yates, Kenneth / Tizard, Ian

    Planta medica

    2007  Volume 73, Issue 12, Page(s) 1260–1266

    Abstract: Stabilization of growth factors in a wound environment is critical to the wound healing process. Here we report on the stabilization of key growth factors by a unique plant cell wall biomaterial. MicroSheets are clear cell wall fragments isolated from ... ...

    Abstract Stabilization of growth factors in a wound environment is critical to the wound healing process. Here we report on the stabilization of key growth factors by a unique plant cell wall biomaterial. MicroSheets are clear cell wall fragments isolated from the non-living water storage cells in the pulp or inner gel of Aloe vera L., which has widely been used for wound healing. It was found that MicroSheets bind to a subset of heparin binding growth factors including basic fibroblast growth factor (bFGF) and keratinocyte growth factor (KGF), two key growth factors in the wound healing process. The binding of bFGF and KGF to MicroSheets was inhibited by heparin and also by a pectic substance isolated from the MicroSheets, indicating that the binding was mediated by this pectic component of the MicroSheet. The binding protected the growth factors against protease digestion. Furthermore, the protective effect was also demonstrated with KGF against digestion by wound fluids and by measuring the biological activity. Thus, these results showed that MicroSheets can stabilize certain critical growth factors in wounds and thereby promote the healing process. Incorporation of a material like MicroSheets provides an important functional element in wound dressings, i. e., growth factor stabilization.
    MeSH term(s) Aloe/metabolism ; Biocompatible Materials/metabolism ; Cell Wall/metabolism ; Fibroblast Growth Factor 2/metabolism ; Fibroblast Growth Factor 7/metabolism ; Materials Testing ; Peptide Hydrolases/metabolism ; Plant Leaves/metabolism ; Plants, Medicinal/metabolism ; Wound Healing/physiology
    Chemical Substances Biocompatible Materials ; Fibroblast Growth Factor 2 (103107-01-3) ; Fibroblast Growth Factor 7 (126469-10-1) ; Peptide Hydrolases (EC 3.4.-)
    Language English
    Publishing date 2007-10
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 123545-x
    ISSN 1439-0221 ; 0032-0943
    ISSN (online) 1439-0221
    ISSN 0032-0943
    DOI 10.1055/s-2007-990225
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.

    Ball, Jordan P / Springer, Michael J / Ni, Yawei / Finger-Baker, Isaac / Martinez, Juan / Hahn, Jessica / Suber, John F / DiMarco, Ashley V / Talton, James D / Cobb, Ronald R

    PloS one

    2017  Volume 12, Issue 5, Page(s) e0177310

    Abstract: The global health community is beginning to understand the burden of norovirus-associated disease, which has a significant impact in both developed and developing countries. Norovirus virus like particle (VLP)-based vaccines are currently under ... ...

    Abstract The global health community is beginning to understand the burden of norovirus-associated disease, which has a significant impact in both developed and developing countries. Norovirus virus like particle (VLP)-based vaccines are currently under development and have been shown to elicit systemic and mucosal immune responses when delivered intranasally. In the present study, we describe the use of a dry powder formulation (GelVac™) with an in situ gelling polysaccharide (GelSite™) extracted from Aloe vera for nasal delivery of a bivalent vaccine formulation containing both GI and GII.4 norovirus VLPs. Dose-ranging studies were performed to identify the optimal antigen dosages based on systemic and mucosal immune responses in guinea pigs and determine any antigenic interference. A dose-dependent increase in systemic and mucosal immunogenicity against each of the VLPs were observed as well as a boosting effect for each VLP after the second dosing. A total antigen dose of ≥50 μg of each GI and GII.4 VLPs was determined to be the maximally immunogenic dose in guinea pigs. The immunogenicity results of this bivalent formulation, taken together with previous work on monovalent GelVac™ norovirus vaccine formulation, provides a basis for future development of this norovirus VLP vaccine.
    MeSH term(s) Administration, Intranasal ; Aloe/chemistry ; Animals ; Caliciviridae Infections/immunology ; Caliciviridae Infections/prevention & control ; Dose-Response Relationship, Drug ; Female ; Gels/chemistry ; Guinea Pigs ; Immunity, Mucosal ; Neutralization Tests ; Norovirus/immunology ; Norovirus/pathogenicity ; Powders/chemistry ; Viral Vaccines/administration & dosage ; Viral Vaccines/chemistry ; Viral Vaccines/immunology
    Chemical Substances Gels ; Powders ; Viral Vaccines
    Language English
    Publishing date 2017-05-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0177310
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation.

    Springer, Michael J / Ni, Yawei / Finger-Baker, Isaac / Ball, Jordan P / Hahn, Jessica / DiMarco, Ashley V / Kobs, Dean / Horne, Bobbi / Talton, James D / Cobb, Ronald R

    Vaccine

    2016  Volume 34, Issue 12, Page(s) 1452–1458

    Abstract: Norovirus is the primary cause of viral gastroenteritis in humans with multiple genotypes currently circulating worldwide. The development of a successful norovirus vaccine is contingent on its ability to induce both systemic and mucosal antibody ... ...

    Abstract Norovirus is the primary cause of viral gastroenteritis in humans with multiple genotypes currently circulating worldwide. The development of a successful norovirus vaccine is contingent on its ability to induce both systemic and mucosal antibody responses against a wide range of norovirus genotypes. Norovirus virus-like particles (VLPs) are known to elicit systemic and mucosal immune responses when delivered intranasally. Incorporation of these VLPs into an intranasal powder vaccine offers the advantage of simplicity and induction of neutralizing systemic and mucosal antibodies. Nasal immunization, which provides the advantage of ease of administration and a mucosal delivery mechanism, faces the real issue of limited nasal residence time due to mucociliary clearance. Herein, we describe a novel dry powder (GelVac™) formulation of GI or GII.4 norovirus VLPs, two dominant circulating genotypes, to identify the optimal antigen dosages based on systemic and mucosal immune responses in guinea pigs. Systemic and mucosal immunogenicity of each of the VLPs was observed in a dose-dependent manner. In addition, a boosting effect was observed after the second dosing of each VLP antigen. With the GelVac™ formulation, a total antigen dose of ≥ 15 μg was determined to be the maximally immunogenic dose for both GI and GII.4 norovirus VLPs based on evaluation for 56 days. Taken together, these results indicate that norovirus VLPs could be used as potential vaccine candidates without using an immunostimulatory adjuvant and provide a basis for the development of a GelVac™ bivalent GI/GII.4 norovirus VLP vaccine.
    MeSH term(s) Administration, Intranasal ; Animals ; Antibodies, Viral/blood ; Dose-Response Relationship, Immunologic ; Female ; Guinea Pigs ; Immunity, Mucosal ; Immunoglobulin G/blood ; Neutralization Tests ; Norovirus ; Powders ; Random Allocation ; Vaccination/methods ; Vaccines, Virus-Like Particle/administration & dosage ; Vaccines, Virus-Like Particle/chemistry ; Vaccines, Virus-Like Particle/immunology ; Viral Vaccines/administration & dosage ; Viral Vaccines/chemistry ; Viral Vaccines/immunology
    Chemical Substances Antibodies, Viral ; Immunoglobulin G ; Powders ; Vaccines, Virus-Like Particle ; Viral Vaccines
    Language English
    Publishing date 2016-02-10
    Publishing country Netherlands
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2016.01.064
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Stabilization of Growth Factors Relevant to Wound Healing by a Plant Cell Wall Biomaterial

    Ni, Yawei / Turner, Debra / Yates, Kenneth / Tizard, Ian

    Planta Medica

    2007  Volume 73, Issue 12, Page(s) 1260–1266

    Abstract: Stabilization of growth factors in a wound environment is critical to the wound healing process. Here we report on the stabilization of key growth factors by a unique plant cell wall biomaterial. MicroSheets are clear cell wall fragments isolated from ... ...

    Abstract Stabilization of growth factors in a wound environment is critical to the wound healing process. Here we report on the stabilization of key growth factors by a unique plant cell wall biomaterial. MicroSheets are clear cell wall fragments isolated from the non-living water storage cells in the pulp or inner gel of ALOE VERA L., which has widely been used for wound healing. It was found that MicroSheets bind to a subset of heparin binding growth factors including basic fibroblast growth factor (bFGF) and keratinocyte growth factor (KGF), two key growth factors in the wound healing process. The binding of bFGF and KGF to MicroSheets was inhibited by heparin and also by a pectic substance isolated from the MicroSheets, indicating that the binding was mediated by this pectic component of the MicroSheet. The binding protected the growth factors against protease digestion. Furthermore, the protective effect was also demonstrated with KGF against digestion by wound fluids and by measuring the biological activity. Thus, these results showed that MicroSheets can stabilize certain critical growth factors in wounds and thereby promote the healing process. Incorporation of a material like MicroSheets provides an important functional element in wound dressings, i. e., growth factor stabilization.
    Keywords Liliaceae ; wound healing ; polysaccharides ; growth factors ; cell wall
    Language English
    Publishing date 2007-09-24
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 123545-x
    ISSN 1439-0221 ; 0032-0943
    ISSN (online) 1439-0221
    ISSN 0032-0943
    DOI 10.1055/s-2007-990225
    Database Thieme publisher's database

    More links

    Kategorien

  10. Article: Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine

    Velasquez, Lissette S / Shira, Samantha / Berta, Alice N / Kilbourne, Jacquelyn / Medi, Babu M / Tizard, Ian / Ni, Yawei / Arntzen, Charles J / Herbst-Kralovetz, Melissa M

    Vaccine. 2011 July 18, v. 29, no. 32

    2011  

    Abstract: The development of a vaccine to prevent norovirus infections has been focused on immunization at a mucosal surface, but has been limited by the low immunogenicity of self-assembling Norwalk virus-like particles (NV VLPs) delivered enterically or at nasal ...

    Abstract The development of a vaccine to prevent norovirus infections has been focused on immunization at a mucosal surface, but has been limited by the low immunogenicity of self-assembling Norwalk virus-like particles (NV VLPs) delivered enterically or at nasal surfaces. Nasal immunization, which offers the advantage of ease of immunization, faces obstacles imposed by the normal process of mucociliary clearance, which limits residence time of applied antigens. Herein, we describe the use of a dry powder formulation (GelVac) of an inert in situ gelling polysaccharide (GelSite) extracted from Aloe vera for nasal delivery of NV VLP antigen. Powder formulations, with or without NV VLP antigen, were similar in structure in dry form or when rehydrated in simulated nasal fluids. Immunogenicity of the dry powder VLP formulation was compared to equivalent antigen/adjuvant liquid formulations in animals. For the GelVac powder, we observed superior NV-specific serum and mucosal (aerodigestive and reproductive tracts) antibody responses relative to liquid formulations. Incorporation of the TLR7 agonist gardiquimod in dry powder formulations did not enhance antibody responses, although its inclusion in liquid formulations did enhance VLP immunogenicity irrespective of the presence or absence of GelSite. We interpret these data as showing that GelSite-based dry powder formulations (1) stabilize the immunogenic structural properties of VLPs and (2) induce systemic and mucosal antibody titers which are equal or greater than those achieved by VLPs plus adjuvant in a liquid formulation. We conclude that in situ gelation of the GelVac dry powder formulation at nasal mucosal surfaces delays mucociliary clearance and thereby prolongs VLP antigen exposure to immune effector sites.
    Keywords Aloe vera ; agonists ; animals ; antigens ; blood serum ; gelation ; immune response ; immunization ; nose ; vaccine development ; vaccines ; virus-like particles
    Language English
    Dates of publication 2011-0718
    Size p. 5221-5231.
    Publishing place Elsevier Ltd
    Document type Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2011.05.027
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

To top